• Cumberland Pharmaceuticals posted a net loss of $3.29 million for quarter ended March 31, 2026, swinging from net income of $1.25 million a year earlier as net revenues fell 22.04% to $9.13 million.
• Operating results turned to an operating loss of $3.13 million from operating income of $1.29 million, while total costs and expenses rose to $12.26 million from $10.42 million.
• Sancuso net revenues climbed to $2.93 million from $2.26 million, Vibativ net revenues increased to $2.12 million from $1.38 million.
• Kristalose net revenues dropped to $981,483 from $3.48 million, while Talicia contributed $1.92 million in net revenues following the start of shipments in October 2025.
• Apotex agreed to acquire portfolio of FDA-approved brands for $100 million in cash, while FDA granted Fast Track designation for ifetroban in Duchenne muscular dystrophy cardiomyopathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001087294-26-000049), on May 08, 2026, and is solely responsible for the information contained therein.